Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24019
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKlotz, Luisa-
dc.contributor.authorLindner, Maren-
dc.contributor.authorGross, Catherina C.-
dc.contributor.authorEschborn, Melanie-
dc.contributor.authorPosevitz-Fejfar, Anita-
dc.contributor.authorSchulte-Mecklenbeck, Andreas-
dc.contributor.authorMeuth, S. G.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorHupperts, Raymond-
dc.contributor.authorMaeurer, M.-
dc.contributor.authorStangel, M.-
dc.contributor.authorLang, M.-
dc.contributor.authorTackenberg, B.-
dc.contributor.authorLysandropoulos, A.-
dc.contributor.authorDecoo, D.-
dc.contributor.authorEveslage, M.-
dc.contributor.authorTurner, Timothy J.-
dc.contributor.authorJagerschmidt, A.-
dc.contributor.authorBar-Or, Amit-
dc.contributor.authorWiendl, Heinz-
dc.date.accessioned2017-07-19T13:19:31Z-
dc.date.available2017-07-19T13:19:31Z-
dc.date.issued2016-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 22, p. 869-869 (Art N° P1646)-
dc.identifier.issn1352-4585-
dc.identifier.urihttp://hdl.handle.net/1942/24019-
dc.description.sponsorshipStudy supported by Sanofi Genzyme. LK: Compensation for serving on scientific advisory boards (Genzyme, Novartis); speaker honoraria/travel support (CSL Behring, Merck Serono, Novartis); research support (Biogen Idec, Novartis). SGM: Received honoraria for lecturing and travel expenses for attending meetings, and has received financial research support from Bayer, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi-Aventis, and Teva. BVW: Financial support/study grants, speaker fees, advisory board membership (Bayer, Biogen, Genzyme/Sanofi, Merck Serono, Novartis, Roche, Teva). RH: Compensation for lectures, advisory boards, consultancy, research grants (Biogen Idec, Merck Serono, Novartis, Sanofi, Teva). MM: Compensation for lectures, advisory boards, consultancy (Bayer, Biogen Idec, Bohringer, Merck Serono, Novartis, Roche, Sanofi, Teva). MS: Received honoraria for scientific lectures or consultancy from Bayer Healthcare, Biogen, Baxter/Baxalta, CSL Behring, Euroimmune, Grifols, Merck-Serono, Novartis, Roche, Sanofi-Aventis, and Teva. His institution received research support from Bayer Healthcare, Biogen Idec, Genzyme, Merck-Serono, Novartis, and Teva. BT: Speaker and consultancy honoraria, travel reimbursements, and unrestricted research grants from Bayer, Biogen, CSL Behring, Grifols, Merck Serono, Novartis, Octapharma, Roche, Sanofi Genzyme, Teva. AL: Educational grants and honoraria as a speaker and member of advisory boards of BAYER, Biogen, TEVA, Novartis, Sanofi Genzyme, Merck. AB-O: Speaking, consultancy fees, and/or grant support (Amplimmune, Biogen Idec, Diogenix, Genentech, Genzyme/Sanofi, GSK, Merck/EMD Serono, Novartis, Ono Pharma, Receptos, Roche, Teva Neuroscience). HW: Compensation for serving on scientific advisory boards (Bayer HealthCare, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi); speaker honoraria and travel support (Bayer Schering AG, Bayer Vital GmbH, Biogen Idec, CSL Behring, Fresenius Medical Care, Genzyme, GSK, GW Pharmaceuticals, Merck Serono, Novartis, Sanofi); compensation as consultant (Biogen Idec, Merck Serono, Novartis, Sanofi).-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.titleEffects of teriflunomide treatment on the CD4(+) T-cell receptor repertoire in patients with relapsing-remitting MS-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 14-17, 2016-
local.bibliographicCitation.conferencename32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-
local.bibliographicCitation.conferenceplaceLondon, ENGLAND-
dc.identifier.epage869-
dc.identifier.spage869-
dc.identifier.volume22-
local.format.pages1-
local.bibliographicCitation.jcatM-
dc.description.notes[Klotz, L.; Lindner, M.; Gross, C. C.; Eschborn, M.; Posevitz-Fejfar, A.; Schulte-Mecklenbeck, A.; Meuth, S. G.; Eveslage, M.; Wiendl, H.] Univ Munster, Munster, Germany. [Van Wijmeersch, B.] Hasselt Univ, Hasselt, Belgium. [Hupperts, R.] Maastricht Univ, Maastricht, Netherlands. [Maeurer, M.] Caritas Hosp, Bad Mergentheim, Germany. [Stangel, M.] Hannover Med Sch, Hannover, Germany. [Lang, M.] Neuropoint Patient Acad, Ulm, Germany. [Tackenberg, B.] Philipps Univ, Giessen, Germany. [Tackenberg, B.] Philipps Univ, Marburg, Germany. [Tackenberg, B.] Univ Clin, Giessen, Germany. [Tackenberg, B.] Univ Clin, Marburg, Germany. [Lysandropoulos, A.] Free Univ Brussels, Erasme Hosp, Brussels, Belgium. [Decoo, D.] AZ Alma, Sijsele, Belgium. [Turner, T. J.] Sanofi Genzyme, Cambridge, MA USA. [Jagerschmidt, A.] Sanofi R&D, Chilly Mazarin, France. [Bar-Or, A.] Montreal Neurol Inst, Montreal, PQ, Canada.-
local.publisher.placeLONDON-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrP1646-
dc.identifier.isi000383267203318-
item.fulltextNo Fulltext-
item.contributorKlotz, Luisa-
item.contributorLindner, Maren-
item.contributorGross, Catherina C.-
item.contributorEschborn, Melanie-
item.contributorPosevitz-Fejfar, Anita-
item.contributorSchulte-Mecklenbeck, Andreas-
item.contributorMeuth, S. G.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorHupperts, Raymond-
item.contributorMaeurer, M.-
item.contributorStangel, M.-
item.contributorLang, M.-
item.contributorTackenberg, B.-
item.contributorLysandropoulos, A.-
item.contributorDecoo, D.-
item.contributorEveslage, M.-
item.contributorTurner, Timothy J.-
item.contributorJagerschmidt, A.-
item.contributorBar-Or, Amit-
item.contributorWiendl, Heinz-
item.fullcitationKlotz, Luisa; Lindner, Maren; Gross, Catherina C.; Eschborn, Melanie; Posevitz-Fejfar, Anita; Schulte-Mecklenbeck, Andreas; Meuth, S. G.; VAN WIJMEERSCH, Bart; Hupperts, Raymond; Maeurer, M.; Stangel, M.; Lang, M.; Tackenberg, B.; Lysandropoulos, A.; Decoo, D.; Eveslage, M.; Turner, Timothy J.; Jagerschmidt, A.; Bar-Or, Amit & Wiendl, Heinz (2016) Effects of teriflunomide treatment on the CD4(+) T-cell receptor repertoire in patients with relapsing-remitting MS. In: MULTIPLE SCLEROSIS JOURNAL, 22, p. 869-869 (Art N° P1646).-
item.accessRightsClosed Access-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.